Literature DB >> 12699131

Impaired nocturnal melatonin secretion in non-dipper hypertensive patients.

Michael Jonas1, Doron Garfinkel, Nava Zisapel, Moshe Laudon, Ehud Grossman.   

Abstract

BACKGROUND: Melatonin plays a role in the biologic regulation of circadian rhythms, including sleep. Melatonin has also been shown to modulate vascular smooth muscle tone and to induce hemodynamic effects in humans.
OBJECTIVE: To evaluate whether melatonin plays a role in the circadian rhythm of blood pressure in hypertensive patients.
METHODS: Sixteen elderly patients with essential hypertension were evaluated. Patients were defined as either dippers (DIP, n = 8) or non-dippers (NDIP, n = 8) according to the nocturnal change in the mean arterial pressure (MAP). 6-Sulfatoxymelatonin (6-SMT), the main melatonin metabolite, was determined by enzyme-linked immunosorbent assay (ELISA) in two separate urine collections, one in the daytime and one during the night.
RESULTS: Both groups of DIP and NDIP hypertensives were comparable in regard to age and sex. During the night, the mean arterial pressure decreased by 10.3 +/- 2.2% in the DIP and increased by 7.5 +/- 1.7% in the NDIP group (p < 0.01). Daily 6-SMT was comparable in DIP (3.28 +/- 0.87 microg/12 h) and NDIP (2.31 +/- 0.68 microg/12 h) (p = 0.39). However, while the DIP presented the physiological nocturnal increase in urinary 6-SMT (mean 8.19 +/- 1.68 microg/ 12 h), this surge of melatonin production was missing in NDIP in whom nocturnal urinary 6-SMT concentrations were not significantly different from daily levels (mean 2.56 +/- 0.79 microg/12 h). The nocturnal change in urinary 6-SMT excretion was positively correlated to the nocturnal change in MAP (R = 0.54; p = 0.031).
CONCLUSIONS: NDIP hypertensive patients differ from DIP hypertensives by having an impaired nocturnal melatonin secretion. Thus, melatonin may play a role in the circadian rhythm of blood pressure in hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12699131

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  33 in total

1.  Long-term effects of melatonin on quality of life and sleep in haemodialysis patients (Melody study): a randomized controlled trial.

Authors:  Marije Russcher; Birgit C P Koch; J Elsbeth Nagtegaal; Frans J van Ittersum; Pieternel C M Pasker-de Jong; E Chris Hagen; Wim Th van Dorp; Bas Gabreëls; Thierry X Wildbergh; Monique M L van der Westerlaken; Carlo A J M Gaillard; Piet M Ter Wee
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

2.  Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial.

Authors:  Frank A J L Scheer; Christopher J Morris; Joanna I Garcia; Carolina Smales; Erin E Kelly; Jenny Marks; Atul Malhotra; Steven A Shea
Journal:  Sleep       Date:  2012-10-01       Impact factor: 5.849

3.  Effects of living at two ambient temperatures on 24-h blood pressure and neuroendocrine function among obese and non-obese humans: a pilot study.

Authors:  Dominika Kanikowska; Maki Sato; Satoshi Iwase; Yuuki Shimizu; Naoki Nishimura; Yoko Inukai; Junichi Sugenoya
Journal:  Int J Biometeorol       Date:  2012-07-21       Impact factor: 3.787

4.  Effects of antenatal, postpartum and post-weaning melatonin supplementation on blood pressure and renal antioxidant enzyme activities in spontaneously hypertensive rats.

Authors:  S K Lee; K N S Sirajudeen; Arunkumar Sundaram; Rahimah Zakaria; H J Singh
Journal:  J Physiol Biochem       Date:  2011-01-06       Impact factor: 4.158

5.  The presence and localization of melatonin receptors in the rat aorta.

Authors:  Martin Schepelmann; Lubos Molcan; Hana Uhrova; Michal Zeman; Isabella Ellinger
Journal:  Cell Mol Neurobiol       Date:  2011-06-22       Impact factor: 5.046

Review 6.  Melatonin, mitochondria and hypertension.

Authors:  Ovidiu C Baltatu; Fernanda G Amaral; Luciana A Campos; Jose Cipolla-Neto
Journal:  Cell Mol Life Sci       Date:  2017-08-08       Impact factor: 9.261

7.  MT2 receptors mediate the inhibitory effects of melatonin on nitric oxide-induced relaxation of porcine isolated coronary arteries.

Authors:  Radhika R Tunstall; Praveen Shukla; Anna Grazul-Bilska; Chengwen Sun; Stephen T O'Rourke
Journal:  J Pharmacol Exp Ther       Date:  2010-10-19       Impact factor: 4.030

8.  Impaired endogenous nighttime melatonin secretion relates to intrarenal renin-angiotensin system activation and renal damage in patients with chronic kidney disease.

Authors:  Sayaka Ishigaki; Naro Ohashi; Shinsuke Isobe; Naoko Tsuji; Takamasa Iwakura; Masafumi Ono; Yukitoshi Sakao; Takayuki Tsuji; Akihiko Kato; Hiroaki Miyajima; Hideo Yasuda
Journal:  Clin Exp Nephrol       Date:  2016-01-07       Impact factor: 2.801

Review 9.  Regulation of circadian blood pressure: from mice to astronauts.

Authors:  Rajiv Agarwal
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-01       Impact factor: 2.894

Review 10.  Role of melatonin in metabolic regulation.

Authors:  Ahmet Korkmaz; Turgut Topal; Dun-Xian Tan; Russel J Reiter
Journal:  Rev Endocr Metab Disord       Date:  2009-12       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.